Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

Author Colombo, M. Google Scholar
Fernandez, I. Google Scholar
Abdurakhmanov, D. Google Scholar
Ferreira, P. A. Autor UNIFESP Google Scholar
Strasser, S. I. Google Scholar
Urbanek, P. Google Scholar
Moreno, C. Google Scholar
Streinu-Cercel, A. Google Scholar
Verheyen, A. Google Scholar
Iraqi, W. Google Scholar
DeMasi, R. Google Scholar
Hill, A. Google Scholar
Laeuffer, J. M. Google Scholar
Lonjon-Domanec, I. Google Scholar
Wedemeyer, H. Google Scholar
Institution Univ Milan
Hosp Univ 12 Octubre
IM Sechenov First Moscow State Med Univ
Universidade Federal de São Paulo (UNIFESP)
Univ Sydney
Charles Univ Prague
Cent Mil Hosp Prague
Univ Libre Brussels
Carol Davila Univ Med & Pharm
Janssen Pharmaceut
Janssen Res & Dev
Janssen Cilag AG
Hannover Med Sch
Abstract Background and aim Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-alpha (PEG-IFN alpha) and ribavirin (RBV) in patients with advanced liver fibrosis caused by HCV genotype 1 (HCV-1).Methods 1782 patients with HCV-1 and bridging fibrosis or compensated cirrhosis were prospectively recruited from 16 countries worldwide, and treated with 12 weeks of TVR plus PEG-IFN/RBV, followed by 12 or 36 weeks of PEG-IFN and RBV (PR) alone dependent on virological response to treatment and previous response type.Results 1587 patients completed 12 weeks of triple therapy and 4 weeks of PR tail (53% cirrhosis, 22% HCV-1a). By week 12, HCV RNA was undetectable in 85% of naives, 88% of relapsers, 80% of partial responders and 72% of null responders. Overall, 931 patients (59%) developed grade 1-4 anaemia (grade 3/4 in 31%), 630 (40%) dose reduced RBV, 332 (21%) received erythropoietin and 157 (10%) were transfused. Age and female gender were the strongest predictors of anaemia. 64 patients (4%) developed a grade 3/4 rash. Discontinuation of TVR due to AEs was necessary in 193 patients (12%). Seven patients died (0.4%, six had cirrhosis).Conclusions in compensated patients with advanced fibrosis due to HCV-1, triple therapy with TVR led to satisfactory rates of safety, tolerability and on-treatment virological response with adequate managements of AEs.
Language English
Sponsor Janssen Pharmaceutics
Date 2014-07-01
Published in Gut. London: Bmj Publishing Group, v. 63, n. 7, p. 1150-1158, 2014.
ISSN 0017-5749 (Sherpa/Romeo, impact factor)
Publisher Bmj Publishing Group
Extent 1150-1158
Origin http://dx.doi.org/10.1136/gutjnl-2013-305667
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000337917900017
URI http://repositorio.unifesp.br/handle/11600/37901

Show full item record




File

Name: WOS000337917900017.pdf
Size: 744.2Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account